New therapeutics in C1INH deficiency: A review of recent studies and advances

Current Allergy and Asthma Reports

Volumn 11, Issue 4, 2011, Pages 300-308

  Parikh, Neil ^a   Riedl, Marc A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bradykinin; C1 inhibitor protein; C1INH deficiency; Clinical studies; Ecallantide; Hereditary angioedema; Icatibant; Kallikrein; Therapeutics; Treatment

Indexed keywords

ADRENALIN; ANDROGEN DERIVATIVE; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; HORMONE DERIVATIVE; ICATIBANT; PLACEBO; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; EMOTIONAL DISORDER; HUMAN; INJECTION SITE REACTION; LARYNX EDEMA; LIVER TOXICITY; MENSTRUATION DISORDER; MUSCLE SPASM; NAUSEA; NOSE CONGESTION; OUTCOME ASSESSMENT; PAIN; PSYCHOSIS; REVIEW; RHINOPHARYNGITIS; SINUSITIS; SYMPTOMATOLOGY; TACHYCARDIA; TREATMENT RESPONSE; VIRILIZATION; VOMITING;

COMPLEMENT C1 INACTIVATOR PROTEINS; GASTROINTESTINAL TRACT; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; LARYNX; SKIN;

EID: 80052452790     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-011-0203-x     Document Type: Review

References (40)

1. Bork K, Meng G, Staubach P et al (2006) Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 119:267-274 (Pubitemid 43255068)
2. Ghebrehiwet B, Randazzo BP, Dunn JT et al (1983) Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 71:1450-1456 (Pubitemid 13098935)
3. Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:193-204. This is an authoritative, up-to-date review of hereditary angioedema pathophysiology with a focus on bradykinin as the primary mediator of symptoms.
4. Joseph K, Tholanikunnel B, Kaplan A (2002) Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci U S A 99:896-900 (Pubitemid 34106607)
5. Joseph K, Shibayama Y, Ghebrehiwet B et al (2001) Factor XIIdependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1. Thromb Haemost 85:119-124 (Pubitemid 32050953)
6. Gompels M, Lock R, Abinun M et al (2005) C1 inhibitor deficiency: consensus document. Clin Exp Immunol 139:379-394 (Pubitemid 40333248)
7. Cugno M, Zanichelli A, Foieni F et al (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 15:69-78
8. Pappalardo E, Caccia S, Suffritti C et al (2008) Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol 25:3536-3544
9. Rosen FS, Pensky J, Donaldson V et al (1965) Hereditary angioneurotic edema: two genetic variants. Science 148:957-958
10. Prada AE, Zahedi K, Davis AE 3rd (1998) Regulation of C1 inhibitor synthesis. Immunobiology 199:377-388 (Pubitemid 28404357)
11. Agostoni A, Cicardi M (1992) Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 pa.Medicine 71:206-215
12. Bork K,Wulff K, Hardt J et al (2009) Hereditary angioedema caused by missensemutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 124:129-134
13. Nzeako U, Frigas E, Tremaine W (2001) Hereditary angioedema: a broad review for clinicians. Arch Intern Med 161:2417-2429 (Pubitemid 33043115)
14. Bork K, Barnstedt S (2003) Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 134:1088-1094 (Pubitemid 38175476)
15. Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31:407-14. Little quantitative research has examined the burden of illness associated with HAE. This publication provides unique insight into the effect of C1INH deficiency on individuals.
16. Bracho FA (2005) Hereditary angioedema. Curr Opin Hematol 12:493-498 (Pubitemid 41546482)
17. Bork K, Staubach P, Eckardt AJ et al (2006) Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 101:619-627 (Pubitemid 43340941)
18. Agostoni A, Aygoren-Pursun E, Binkley KE et al (2004) Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114:S51-S131 (Pubitemid 39200689)
19. Longhurst HJ, Bork K (2006) Hereditary angioedema: causes, manifestations, and treatment. Br J Hosp Med (Lond) 67:654-657 (Pubitemid 46094089)
20. Frank MM, Sergent JS, Kane MA et al (1972) Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A doubleblind study. N Engl J Med 286:808-812
21. Agostoni A, Marasini B, Cicardi M et al (1978) Hepatic function and fibrinolysis in patients with hereditary angioedema undergoing long-term treatment with tranexamic acid. Allergy 33:216-221 (Pubitemid 9064507)
22. Gelfand JA, Sherins RJ, Alling DW et al (1976) Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 295:1444-1448 (Pubitemid 8003704)
23. Pitts JS, Donaldson VH, Forristal J et al (1978) Remissions induced in hereditary angioneurotic edema with an attenuated androgen (danazol): correlation between concentrations of C1-inhibitor and the fourth and second components of complement. J Lab Clin Med 92:501-507 (Pubitemid 9027455)
24. Agostoni A, Cicardi M, Martignoni GC et al (1980) Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. J Allergy Clin Immunol 65:75-9 (Pubitemid 10211125)
25. Bork K, Bygum A, Hardt J (2008) Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 100:153-161 (Pubitemid 351238551)
26. Craig TJ (2008) Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc 29:225-231
27. Androgens. In: Brunton LL, Lazo JS, Parker KL: Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th edition. McGraw-Hill, 2005.
28. Bowen T, Brosz J, Brosz K et al (2010) Management of hereditary angioedema: 2010 Canadian approach. Allergy Asthma Clin Immunol 6:20
29. Zuraw B (2010) HAE therapies: past, present, and future. Allergy Asthma Clin Immunol 6:23
30. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124:801-8. This was a recent rigorous phase 3 study that demonstrated important dose-related efficacy for pasteurized C1INH therapy in treating HAE attacks.
31. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22. This was a recent paper reporting pivotal outcomes data from phase 3 studies of nanofiltered C1INH for both acute and long-term prophylactic treatment of HAE.
32. Zuraw B, Cicardi M, Levy R, et al. Recombinant human C1- inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010;126:821-7. This article reported pivotal phase 3 study results for the efficacy and safety of rhC1INH in treating HAE attacks.
33. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363:523-31. This article reported initial phase 3 study data on the efficacy and safety of ecallantide in treating HAE attacks.
34. CicardiM, Banerji A, Bracho F, et al. Icatibant, a new bradykininreceptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363:532-41. This article reported the pivotal study data from two controlled phase 3 studies (FAST-1 and FAST-2) investigating the efficacy and safety of icatibant in treating HAE attacks.
35. Price DD, Finniss DG, Benedetti F (2008) A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 59:565-590
36. Bowen T, Cicardi M, Farkas H, et al. 2010 international consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6:24. This is a recent expert consensus document incorporating new HAE therapeutics into the management approach. Additional international, evidence-based consensus documents are in development.
37. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6:22 This article provides important data and expert opinion regarding the benefits and potential risks of patient selfadministered therapy in managing HAE.
38. Longhurst HJ, Carr S, Khair K (2007) C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 147:11-17 (Pubitemid 44915550)
39. Levy RJ, Lumry WR, McNeil DL et al (2010) EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523-529
40. Lumry W, Li HH, Levy RJ, et al. Results from FAST-3: a phase 3, randomized, double-blind, placebo-controlled, multicenter study of subcutaneous icatibant in subjects with acute attacks of hereditary angioedema [oral abstract]. Presented at the American Academy of Asthma, Allergy, and Immunology, San Francisco, CA. March 18-22, 2011.